Secretory sphingomyelinase in health and disease

Biological Chemistry

Volumn 396, Issue 6-7, 2015, Pages 707-736

  Kornhuber, Johannes ^a   Rhein, Cosima ^a   Müller, Christian P ^a   Mühle, Christiane ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Ceramide; Inflammation; Lipids; Secretory sphingomyelinase; Sphingomyelin; Sphingomyelinase

Indexed keywords

SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; CERAMIDE; SPHINGOMYELIN;

ATHEROSCLEROSIS; BRAIN FUNCTION; CELL MIGRATION; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME KINETICS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; LUNG EDEMA; NIEMANN PICK DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PH; PHARMACOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SEPSIS; ANIMAL; INFLAMMATION; METABOLISM; MUTATION;

ANIMALS; CERAMIDES; HUMANS; INFLAMMATION; MUTATION; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS;

EID: 84943617743     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2015-0109     Document Type: Review

References (277)

1. 2+-stimulated sphingomyelinase deficiency in type B Niemann-Pick disease. Eur. J. Pediatr. 158, 953.
2. Albouz, S., Hauw, J. J., Berwald-Netter, Y., Boutry, J. M., Bourdon, R., and Baumann, N. (1981). Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures. Biomedicine 35, 218-220.
3. Albouz, S., Vanier, M. T., Hauw, J. J., Le Saux, F., Boutry, J. M., and Baumann, N. (1983). Effect of tricyclic antidepressants on sphingomyelinase and other sphingolipid hydrolases in C6 cultured glioma cells. Neurosci. Lett. 36, 311-315.
4. Andrews, N. W., Almeida, P. E., and Corrotte, M. (2014). Damage control: cellular mechanisms of plasma membrane repair. Trends Cell Biol. 24, 734-742.
5. Arenz, C. (2010). Small molecule inhibitors of acid sphingomyelinase. Cell. Physiol. Biochem. 26, 1-8.
6. Arunachalam, B., Phan, U. T., Geuze, H. J., and Cresswell, P. (2000). Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. USA 97, 745-750.
7. Assaf, S. Y. and Chung, S. H. (1984). Release of endogenous Zn2+ from brain tissue during activity. Nature 308, 734-736.
8. Balsinde, J., Balboa, M. A., and Dennis, E. A. (1997). Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis. J. Biol. Chem. 272, 20373-20377.
9. Barceló-Coblijn, G., Martin, M. L., de Almeida, R. F. M., Noguera-Salvà, M. A., Marcilla-Etxenike, A., Guardiola-Serrano, F., Lüth, A., Kleuser, B., Halver, J. E., and Escribá, P. V. (2011). Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. USA 108, 19569-19574.
10. Bartelsen, O., Lansmann, S., Nettersheim, M., Lemm, T., Ferlinz, K., and Sandhoff, K. (1998). Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification, processing and enzymatic characterization. J. Biotechnol. 63, 29-40.
11. Billich, A. and Baumruker, T. (2008). Sphingolipid metabolizing enzymes as novel therapeutic targets. In: Lipids in Health and Disease, Vol. 49, P. J. Quinn and X. Wang, eds. (Springer), pp. 487-522.
12. Bowser, P. A. and Gray, G. M. (1978). Sphingomyelinase in pig and human epidermis. J. Invest. Dermatol. 70, 331-335.
13. Brady, R. O., Kanfer, J. N., Mock, M. B., and Fredrickson, D. S. (1966). The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc. Natl. Acad. Sci. USA 55, 366-369.
14. Brand, I. A. and Kleineke, J. (1996). Intracellular zinc movement and its effect on the carbohydrate metabolism of isolated rat hepatocytes. J. Biol. Chem. 271, 1941-1949.
15. Buxaderas, S. C. and Farré-Rovira, R. (1985). Whole blood and serum zinc levels in relation to sex and age. Rev. Esp. Fisiol. 41, 463-470.
16. Callahan, J. W., Jones, C. S., Davidson, D. J., and Shankaran, P. (1983). The active site of lysosomal sphingomyelinase: evidence for the involvement of hydrophobic and ionic groups. J. Neurosci. Res. 10, 151-163.
17. Canals, D., Perry, D. M., Jenkins, R. W., and Hannun, Y. A. (2011). Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br. J. Pharmacol. 163, 694-712.
18. Charruyer, A., Grazide, S., Bezombes, C., Müller, S., Laurent, G., and Jaffrézou, J. P. (2005). UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J. Biol. Chem. 280, 19196-19204.
19. Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994). Apoptotic signaling through CD95 (Fas/Apo-1). activates an acidic sphingomyelinase. J. Exp. Med. 180, 1547-1552.
20. Claus, R. A., Bunck, A. C., Bockmeyer, C. L., Brunkhorst, F. M., Lösche, W., Kinscherf, R., and Deigner, H.-P. (2005). Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J. 19, 1719-1721.
21. Cohen, R. and Barenholz, Y. (1978). Correlation between the thermotropic behavior of sphingomyelin liposomes and sphingomyelin hydrolysis by sphingomyelinase of Staphylococcus aureus. Biochim. Biophys. Acta 509, 181-187.
22. Corrotte, M., Almeida, P. E., Tam, C., Castro-Gomes, T., Fernandes, M. C., Millis, B. A., Cortez, M., Miller, H., Song, W., Maugel, T. K., et al. (2013). Caveolae internalization repairs wounded cells and muscle fibers. eLife 2, e00926.
23. Csermely, P., Fodor, P., and Somogyi, J. (1987). The tumor promoter tetradecanoylphorbol-13-acetate elicits the redistribution of heavy metals in subcellular fractions of rabbit thymocytes as measured by plasma emission spectroscopy. Carcinogenesis 8, 1663-1666.
24. Deevska, G. M., Sunkara, M., Morris, A. J., and Nikolova-Karakashian, M. N. (2012). Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/-mice fed on a high-fat diet. Biosci. Rep. 32, 479-490.
25. Defour, A., Van der Meulen, J. H., Bhat, R., Bigot, A., Bashir, R., Nagaraju, K., and Jaiswal, J. K. (2014). Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis. 5, e1306.
26. Deng, H., Xiu, X., and Jankovic, J. (2014). Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol. Neurobiol., in press.
27. Desnick, J. P., Kim, J., He, X., Wasserstein, M. P., Simonaro, C. M., and Schuchman, E. H. (2010). Identification and characterization of eight novel SMPD1 mutations causing types A and B Niemann-Pick disease. Mol. Med. 16, 316-321.
28. Devlin, C. M., Leventhal, A. R., Kuriakose, G., Schuchman, E. H., Williams, K. J., and Tabas, I. (2008). Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler. Thromb. Vasc. Biol. 28, 1723-1730.
29. Devlin, C., Pipalia, N. H., Liao, X., Schuchman, E. H., Maxfield, F. R., and Tabas, I. (2010). Improvement in lipid and protein trafficking in Niemann-Pick C1 cells by correction of a secondary enzyme defect. Traffic 11, 601-615.
30. Dhami, R. and Schuchman, E. H. (2004). Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem. 279, 1526-1532.
31. Dinkla, S., Wessels, K., Verdurmen, W. P. R., Tomelleri, C., Cluitmans, J. C. A., Fransen, J., Fuchs, B., Schiller, J., Joosten, I., Brock, R., et al. (2012). Functional consequences of sphingomyelinase-induced changes in erythrocyte membrane structure. Cell Death Dis. 3, e410.
32. Doehner, W., Bunck, A. C., Rauchhaus, M., von Haehling, S., Brunkhorst, F. M., Cicoira, M., Tschope, C., Ponikowski, P., Claus, R. A., and Anker, S. D. (2007). Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur. Heart J. 28, 821-828.
33. Don, A. S., Lim, X. Y., and Couttas, T. A. (2014). Re-configuration of sphingolipid metabolism by oncogenic transformation. Biomolecules 4, 315-353.
34. Donangelo, C. M. and Chang, G. W. (1981). An enzymatic assay for available zinc in plasma and serum. Clin. Chim. Acta 113, 201-206.
35. Drachmann, T., Mathiessen, J. H., Pedersen, M. H., and Hellgren, L. I. (2007). The source of dietary fatty acids alters the activity of secretory sphingomyelinase in the rat. Eur. J. Lipid Sci. Technol. 109, 1003-1009.
36. Draeger, A. and Babiychuk, E. B. (2013). Ceramide in plasma membrane repair. Handb. Exp. Pharmacol. 216, 341-353.
37. Driessen, M., Weitz, G., Brouwer-Kelder, E. M., Donker-Koopman, W. E., Bastiaannet, J., Sandhoff, K., Barranger, J. A., Tager, J. M., and Schram, A. W. (1985). The effect of detergents on immunoprecipitability of lysosomal sphingomyelinase. Biochim. Biophys. Acta 841, 97-102.
38. Drobnik, W., Liebisch, G., Audebert, F. X., Fröhlich, D., Glück, T., Vogel, P., Rothe, G., and Schmitz, G. (2003). Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J. Lipid Res. 44, 754-761.
39. Dumitru, C. A. and Gulbins, E. (2006). TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene 25, 5612-5625.
40. Eckhardt, M. (2010). Pathology and current treatment of neurodegenerative sphingolipidoses. Neuromolecular. Med. 12, 362-382.
41. Edelmann, B., Bertsch, U., Tchikov, V., Winoto-Morbach, S., Perrotta, C., Jakob, M., Adam-Klages, S., Kabelitz, D., and Schütze, S. (2011). Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes. EMBO J. 30, 379-394.
42. Erickson, A. H. and Blobel, G. (1983). Carboxyl-terminal proteolytic processing during biosynthesis of the lysosomal enzymes β-glucuronidase and cathepsin D. Biochemistry 22, 5201-5205.
43. Ferlinz, K., Hurwitz, R., Vielhaber, G., Suzuki, K., and Sandhoff, K. (1994). Occurrence of two molecular forms of human acid sphingomyelinase. Biochem. J. 301, 855-862.
44. Ferlinz, K., Hurwitz, R., Moczall, H., Lansmann, S., Schuchman, E. H., and Sandhoff, K. (1997). Functional characterization of the N-glycosylation sites of human acid sphingomyelinase by sitedirected mutagenesis. Eur. J. Biochem. 243, 511-517.
45. Fernandes, M. C., Cortez, M., Flannery, A. R., Tam, C., Mortara, R. A., and Andrews, N. W. (2011). Trypanosoma cruzi subverts the sphingomyelinase-mediated plasma membrane repair pathway for cell invasion. J. Exp. Med. 208, 909-921.
46. Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., Yang, J., and Duerksen-Hughes, P. J. (2012). Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J. Alzheimers Dis. 29, 537-547.
47. Foo, J. N., Liany, H., Bei, J. X., Yu, X. Q., Liu, J., Au, W. L., Prakash, K. M., Tan, L. C., and Tan, E. K. (2013). Rare lysosomal enzyme gene SMPD1 variant (p. R591C). associates with Parkinson's disease. Neurobiol. Aging 34, 2890-2895.
48. Frederickson, C. J. and Moncrieff, D. W. (1994). Zinc-containing neurons. Biol. Signals 3, 127-139.
49. Fujii, S., Yoshida, A., Sakurai, S., Morita, M., Tsukamoto, K., Ikezawa, H., and Ikeda, K. (2004). Chromogenic assay for the activity of sphingomyelinase from Bacillus cereus and its application to the enzymatic hydrolysis of lysophospholipids. Biol. Pharm. Bull. 27, 1725-1729.
50. Gan-Or, Z., Ozelius, L. J., Bar-Shira, A., Saunders-Pullman, R., Mirelman, A., Kornreich, R., Gana-Weisz, M., Raymond, D., Rozenkrantz, L., Deik, A., et al. (2013). The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80, 1606-1610.
51. Gault, C. R., Obeid, L. M., and Hannun, Y. A. (2010). An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol. 688, 1-23.
52. Göggel, R., Winoto-Morbach, S., Vielhaber, G., Imai, Y., Lindner, K., Brade, L., Brade, H., Ehlers, S., Slutsky, A. S., Schütze, S., et al. (2004). PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat. Med. 10, 155-160.
53. Goni, F. M. and Alonso, A. (2002). Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 531, 38-46.
54. 2+-dependent sphingomyelinase activity in the serum of patients with type 2 diabetes is elevated. Horm. Metab. Res. 35, 506-507.
55. Gracia-Garcia, P., Rao, V., Haughey, N. J., Ratnam Banduru, V. V., Smith, G., Rosenberg, P. B., Lobo, A., Lyketsos, C. G., and Mielke, M. M. (2011). Elevated plasma ceramides in depression. J. Neuropsychiatry Clin. Neurosci. 23, 215-218.
56. Grammatikos, G., Mühle, C., Ferreiros, N., Schroeter, S., Bogdanou, D., Schwalm, S., Hintereder, G., Kornhuber, J., Zeuzem, S., Sarrazin, C., et al. (2014). Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochim. Biophys. Acta 1841, 1012-1020.
57. Grassmé, H., Gulbins, E., Brenner, B., Ferlinz, K., Sandhoff, K., Harzer, K., Lang, F., and Meyer, T. F. (1997). Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 91, 605-615.
58. Grassmé, H., Schwarz, H., and Gulbins, E. (2001). Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 284, 1016-1030.
59. Grassmé, H., Jendrossek, V., Riehle, A., von Kürthy, G., Berger, J., Schwarz, H., Weller, M., Kolesnick, R., and Gulbins, E. (2003). Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9, 322-330.
60. Grassmé, H., Riehle, A., Wilker, B., and Gulbins, E. (2005). Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 280, 26256-26262.
61. Guarino, A. J., Tulenko, T. N., and Wrenn, S. P. (2006). Sphingomyelinase-to-LDL molar ratio determines low density lipoprotein aggregation size: biological significance. Chem. Phys. Lipids 142, 33-42.
62. Gulbins, E. and Kolesnick, R. (2000). Measurement of sphingomyelinase activity. Methods Enzymol. 322, 382-388.
63. Gulbins, E., Palmada, M., Reichel, M., Lüth, A., Böhmer, C., Amato, D., Müller, C. P., Tischbirek, C. H., Groemer, T. W., Tabatabai, G., et al. (2013). Acid sphingomyelinase/ceramide system mediates effects of antidepressant drugs. Nat. Med. 19, 934-938.
64. Gupta, V. R., Patel, H. K., Kostolansky, S. S., Ballivian, R. A., Eichberg, J., and Blanke, S. R. (2008). Sphingomyelin functions as a novel receptor for Helicobacter pylori VacA. PLoS Pathog. 4, e1000073.
65. Haimovitz-Friedman, A., Cordon-Cardo, C., Bayoumy, S., Garzotto, M., McLoughlin, M., Gallily, R., Edwards, C. K., III, Schuchman, E. H., Fuks, Z., and Kolesnick, R. (1997). Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 186, 1831-1841.
66. Hammad, S. M., Truman, J. P., Al Gadban, M. M., Smith, K. J., Twal, W. O., and Hamner, M. B. (2012). Altered blood sphingolipidomics and elevated plasma inflammatory cytokines in combat veterans with post-traumatic stress disorder. Neurobiol. Lipids 10, 2.
67. Harzer, K. and Benz, H. U. (1973). Letters: a simple sphingomyelinase determination for Niemann-Pick disease: differential diagnosis of types A, B and C. J. Neurochem. 21, 999-1001.
68. Hasilik, A. (1992). The early and late processing of lysosomal enzymes: proteolysis and compartmentation. Experientia 48, 130-151.
69. Hauck, C. R., Grassmé, H., Bock, J., Jendrossek, V., Ferlinz, K., Meyer, T. F., and Gulbins, E. (2000). Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett. 478, 260-266.
70. He, X. and Schuchman, E. H. (2012). Potential role of acid sphingomyelinase in environmental health. Zhong. Nan. Da. Xue. Xue. Bao. Yi. Xue. Ban. 37, 109-125.
71. He, X., Miranda, S. R., Xiong, X., Dagan, A., Gatt, S., and Schuchman, E. H. (1999). Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim. Biophys. Acta 1432, 251-264.
72. He, X., Chen, F., Dagan, A., Gatt, S., and Schuchman, E. H. (2003). A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal. Biochem. 314, 116-120.
73. Hendrich, A. B. and Michalak, K. (2003). Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr. Drug Targets 4, 23-30.
74. Henry, B., Möller, C., Dimanche-Boitrel, M. T., Gulbins, E., and Becker, K. A. (2013). Targeting the ceramide system in cancer. Cancer Lett. 332, 286-294.
75. Holopainen, J. M., Medina, O. P., Metso, A. J., and Kinnunen, P. K. J. (2000). Sphingomyelinase activity associated with human plasma low density lipoprotein. J. Biol. Chem. 275, 16484-16489.
76. Horinouchi, K., Erlich, S., Perl, D. P., Ferlinz, K., Bisgaier, C. L., Sandhoff, K., Desnick, R. J., Stewart, C. L., and Schuchman, E. H. (1995). Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat. Genet. 10, 288-293.
77. Hurwitz, R., Ferlinz, K., and Sandhoff, K. (1994a). The tricyclic antidepressants desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol. Chem. Hoppe Seyler 375, 447-450.
78. Hurwitz, R., Ferlinz, K., Vielhaber, G., Moczall, H., and Sandhoff, K. (1994b). Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. J. Biol. Chem. 269, 5440-5445.
79. Ioannou, Y. A., Bishop, D. F., and Desnick, R. J. (1992). Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J. Cell Biol. 119, 1137-1150.
80. Jan, J. T., Chatterjee, S., and Griffin, D. E. (2000). Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide. J. Virol. 74, 6425-6432.
81. Jbeily, N., Suckert, I., Gonnert, F. A., Acht, B., Bockmeyer, C. L., Grossmann, S. D., Blaess, M. F., Lueth, A., Deigner, H. P., Bauer, M., et al. (2013). Hyperresponsiveness of mice deficient in plasma-secreted sphingomyelinase reveals its pivotal role in early phase of host response. J. Lipid Res. 54, 410-424.
82. Jenkins, R. W., Canals, D., and Hannun, Y. A. (2009). Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell. Signal. 21, 836-846.
83. Jenkins, R. W., Canals, D., Idkowiak-Baldys, J., Simbari, F., Roddy, P., Perry, D. M., Kitatani, K., Luberto, C., and Hannun, Y. A. (2010). Regulated secretion of acid sphingomyelinase: implications for selectivity of ceramide formation. J. Biol. Chem. 285, 35706-35718.
84. Jenkins, R. W., Clarke, C. J., Canals, D., Snider, A. J., Gault, C. R., Heffernan-Stroud, L., Wu, B. X., Simbari, F., Roddy, P., Kitatani, K., et al. (2011a). Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase. J. Biol. Chem. 286, 13292-13303.
85. Jenkins, R. W., Idkowiak-Baldys, J., Simbari, F., Canals, D., Roddy, P., Riner, C. D., Clarke, C. J., and Hannun, Y. A. (2011b). A novel mechanism of lysosomal acid sphingomyelinase maturation - requirement for carboxy-terminal proteolytic processing. J. Biol. Chem. 286, 3777-3788.
86. Jenkins, R. W., Clarke, C. J., Lucas, J. T., Jr., Shabbir, M., Wu, B. X., Simbari, F., Mueller, J., Hannun, Y. A., Lazarchick, J., and Shirai, K. (2013). Evaluation of the role of secretory sphingomyelinase and bioactive sphingolipids as biomarkers in hemophagocytic lymphohistiocytosis. Am. J. Hematol. 88, E265-E272.
87. Jeong, T., Schissel, S. L., Tabas, I., Pownall, H. J., Tall, A. R., and Jiang, X. (1998). Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest. 101, 905-912.
88. Jiang, L. J., Maret, W., and Vallee, B. L. (1998). The glutathione redox couple modulates zinc transfer from metallothionein to zincdepleted sorbitol dehydrogenase. Proc. Natl. Acad. Sci. USA 95, 3483-3488.
89. Jobb, E. and Callahan, J. W. (1987). The subunit of human sphingomyelinase is not the same size in all tissues: studies with a polyclonal rabbit serum. J. Inher. Metab. Dis. 10(Suppl. 2), 326-328.
90. Jones, C. S., Shankaran, P., and Callahan, J. W. (1981). Purification of sphingomyelinase to apparent homogeneity by using hydrophobic chromatography. Biochem. J. 195, 373-382.
91. Jones, C. S., Shankaran, P., Davidson, D. J., Poulos, A., and Callahan, J. W. (1983). Studies on the structure of sphingomyelinase. Amino acid composition and heterogeneity on isoelectric focusing. Biochem. J. 209, 291-297.
92. Kim, Y. and Sun, H. (2012). ASM-3 Acid sphingomyelinase functions as a positive regulator of the DAF-2/AGE-1 signaling pathway and serves as a novel anti-aging target. PLoS One 7, e45890.
93. Kinnunen, P. K. and Holopainen, J. M. (2002). Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis? Trends Cardiovasc. Med. 12, 37-42.
94. Kiprianos, A. P., Morgan, M. D., Little, M. A., Harper, L., Bacon, P. A., and Young, S. P. (2012). Elevated active secretory sphingomyelinase in antineutrophil cytoplasmic antibody-associated primary systemic vasculitis. Ann. Rheum. Dis. 71, 1100-1102.
95. Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010). Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463, 549-553.
96. Kobayashi, K., Nagata, E., Sasaki, K., Harada-Shiba, M., Kojo, S., and Kikuzaki, H. (2013). Increase in secretory sphingomyelinase activity and specific ceramides in the aorta of apolipoprotein E knockout mice during aging. Biol. Pharm. Bull. 36, 1192-1196.
97. Kolter, T. and Sandhoff, K. (2005). Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu. Rev. Cell Dev. Biol. 21, 81-103.
98. Kölzer, M., Arenz, C., Ferlinz, K., Werth, N., Schulze, H., Klingenstein, R., and Sandhoff, K. (2003). Phosphatidylinositol-3, 5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol. Chem. 384, 1293-1298.
99. Kölzer, M., Ferlinz, K., Bartelsen, O., Hoops, S. L., Lang, F., and Sandhoff, K. (2004a). Functional characterization of the postulated intramolecular sphingolipid activator protein domain of human acid sphingomyelinase. Biol. Chem. 385, 1193-1195.
100. Kölzer, M., Werth, N., and Sandhoff, K. (2004b). Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 559, 96-98.
101. Kornfeld, S. (1987). Trafficking of lysosomal enzymes. FASEB J. 1, 462-468.
102. Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J., and Gulbins, E. (2008). Identification of new functional inhibitors of acid sphingomyelinase using a structureproperty-activity relation model. J. Med. Chem. 51, 219-237.
103. Kornhuber, J., Tripal, P., Reichel, M., Mühle, C., Rhein, C., Muehlbacher, M., Groemer, T. W., and Gulbins, E. (2010). Functional inhibitors of acid sphingomyelinase (FIASMAs).: a novel pharmacological group of drugs with broad clinical applications. Cell. Physiol. Biochem. 26, 9-20.
104. Kornhuber, J., Muehlbacher, M., Trapp, S., Pechmann, S., Friedl, A., Reichel, M., Mühle, C., Terfloth, L., Groemer, T. W., Spitzer, G. M., et al. (2011). Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One 6, e23852.
105. Kornhuber, J., Müller, C. P., Becker, K. A., Reichel, M., and Gulbins, E. (2014). The ceramide system as a novel antidepressant target. Trends Pharmacol. Sci. 35, 293-304.
106. Kott, M., Elke, G., Reinicke, M., Winoto-Morbach, S., Schädler, D., Zick, G., Frerichs, U., Weiler, N., and Schütze, S. (2014). Acid sphingomyelinase serum activity predicts mortality in intensive care unit patients after systemic inflammation: a prospective cohort study. PLoS One 9, e112323.
107. Krishnan, V. and Nestler, E. J. (2008). The molecular neurobiology of depression. Nature 455, 894-902.
108. Lai, J., Moxey, A., Nowak, G., Vashum, K., Bailey, K., and McEvoy, M. (2012). The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J. Affect. Disord. 136, e31-e39.
109. Lang, P. A., Schenck, M., Nicolay, J. P., Becker, J. U., Kempe, D. S., Lupescu, A., Koka, S., Eisele, K., Klarl, B. A., Rübben, H., et al. (2007). Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat. Med. 13, 164-170.
110. Langmann, T., Buechler, C., Ries, S., Schaeffler, A., Aslanidis, C., Schuierer, M., Weiler, M., Sandhoff, K., de Jong, P. J., and Schmitz, G. (1999). Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. J. Lipid Res. 40, 870-880.
111. Lansmann, S., Ferlinz, K., Hurwitz, R., Bartelsen, O., Glombitza, G., and Sandhoff, K. (1996). Purification of acid sphingomyelinase from human placenta: characterization and N-terminal sequence. FEBS Lett. 399, 227-231.
112. Lansmann, S., Schuette, C. G., Bartelsen, O., Hoernschemeyer, J., Linke, T., Weisgerber, J., and Sandhoff, K. (2003). Human acid sphingomyelinase. Eur. J. Biochem. 270, 1076-1088.
113. Lee, C. Y., Krimbou, L., Vincent, J., Bernard, C., Larramée, P., Genest, J., Jr., and Marcil, M. (2003). Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1). gene is associated with low HDL cholesterol. Hum. Genet. 112, 552-562.
114. Lee, J. K., Jin, H. K., Park, M. H., Kim, B. R., Lee, P. H., Nakauchi, H., Carter, J. E., He, X., Schuchman, E. H., and Bae, J. S. (2014). Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. J. Exp. Med. 211, 1551-1570.
115. Leger, A. J., Mosquea, L. M., Li, L., Chuang, W., Pacheco, J., Taylor, K., Luo, Z., Piepenhagen, P., Ziegler, R., Moreland, R., et al. (2011). Adeno-associated virus-mediated expression of acid sphingomyelinase decreases atherosclerotic lesion formation in apolipoprotein E-/-mice. J. Gene Med. 13, 324-332.
116. Levenson, C. W. (2006). Zinc: the new antidepressant? Nutr. Rev. 64, 39-42.
117. Li, X., Gulbins, E., and Zhang, Y. (2012). Oxidative stress triggers Ca-dependent lysosome trafficking and activation of acid sphingomyelinase. Cell. Physiol. Biochem. 30, 815-826.
118. Lin, X., Hengartner, M. O., and Kolesnick, R. (1998). Caenorhabditis elegans contains two distinct acid sphingomyelinases. J. Biol. Chem. 273, 14374-14379.
119. Linke, T., Wilkening, G., Lansmann, S., Moczall, H., Bartelsen, O., Weisgerber, J., and Sandhoff, K. (2001). Stimulation of acid sphingomyelinase activity by lysosomal lipids and sphingolipid activator proteins. Biol. Chem. 382, 283-290.
120. Little, C. and Otnäss, A. B. (1975). The metal ion dependence of phospholipase C from Bacillus cereus. Biochim. Biophys. Acta 391, 326-333.
121. López-Montero, I., Vélez, M., and Devaux, P. F. (2007). Surface tension induced by sphingomyelin to ceramide conversion in lipid membranes. Biochim. Biophys. Acta 1768, 553-561.
122. Madra, M. and Sturley, S. L. (2010). Niemann-Pick type C pathogenesis and treatment: from statins to sugars. Clin. Lipidol. 5, 387-395.
123. Magenau, A., Benzing, C., Proschogo, N., Don, A. S., Hejazi, L., Karunakaran, D., Jessup, W., and Gaus, K. (2011). Phagocytosis of IgG-coated polystyrene beads by macrophages induces and requires high membrane order. Traffic 12, 1730-1743.
124. Maor, I., Mandel, H., and Aviram, M. (1995). Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-ketocholesterol. Arterioscler. Thromb. Vasc. Biol. 15, 1378-1387.
125. Marathe, S., Schissel, S. L., Yellin, M. J., Beatini, N., Mintzer, R., Williams, K. J., and Tabas, I. (1998). Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramidemediated cell signaling. J. Biol. Chem. 273, 4081-4088.
126. Marathe, S., Kuriakose, G., Williams, K. J., and Tabas, I. (1999). Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 19, 2648-2658.
127. Marathe, S., Choi, Y., Leventhal, A. R., and Tabas, I. (2000a). Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation. Arterioscler. Thromb. Vasc. Biol. 20, 2607-2613.
128. Marathe, S., Miranda, S. R. P., Devlin, C., Johns, A., Kuriakose, G., Williams, K. J., Schuchman, E. H., and Tabas, I. (2000b). Creation of a mouse model for non-neurological (type B). Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. Hum. Mol. Genet. 9, 1967-1976.
129. Maroudas, A., Weinberg, P. D., Parker, K. H., and Winlove, C. P. (1988). The distributions and diffusivities of small ions in chondroitin sulphate, hyaluronate and some proteoglycan solutions. Biophys. Chem. 32, 257-270.
130. McCollister, B. D., Myers, J. T., Jones-Carson, J., Voelker, D. R., and Vázquez-Torres, A. (2007). Constitutive acid sphingomyelinase enhances early and late macrophage killing of Salmonella enterica serovar Typhimurium. Infect. Immun. 75, 5346-5352.
131. Mendis, S. (1989). Magnesium, zinc, and manganese in atherosclerosis of the aorta. Biol. Trace Elem. Res. 22, 251-256.
132. Menkin, V. (1934). Studies on inflammation: X. The cytological picture of an inflammatory exudate in relation to its hydrogen ion concentration. Am. J. Pathol. 10, 193-210.
133. Mielke, M. M., Haughey, N. J., Bandaru, V. V., Weinberg, D. D., Darby, E., Zaidi, N., Pavlik, V., Doody, R. S., and Lyketsos, C. G. (2011). Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J. Alzheimers Dis. 27, 259-269.
134. Mielke, M. M., Maetzler, W., Haughey, N. J., Bandaru, V. V. R., Savica, R., Deuschle, C., Gasser, T., Hauser, A. K., Gräber-Sultan, S., Schleicher, E., et al. (2013). Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLoS One 8, e73094.
135. Milanino, R., Marrella, M., Gasperini, R., Pasqualicchio, M., and Velo, G. (1993). Copper and zinc body levels in inflammation: an overview of the data obtained from animal and human studies. Agents Actions 39, 195-209.
136. Milhas, D., Clarke, C. J., and Hannun, Y. A. (2010). Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids. FEBS Lett. 584, 1887-1894.
137. Miller, M. E., Adhikary, S., Kolokoltsov, A. A., and Davey, R. A. (2012). Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J. Virol. 86, 7473-7483.
138. Mintzer, R. J., Appell, K. C., Cole, A., Johns, A., Pagila, R., Polokoff, M. A., Tabas, I., Snider, R. M., and Meurer-Ogden, J. A. (2005). A novel high-throughput screening format to identify inhibitors of secreted acid sphingomyelinase. J. Biomol. Screen. 10, 225-234.
139. Miranda, S. R. P., He, X., Simonaro, C. M., Gatt, S., Dagan, A., Desnick, R. J., and Schuchman, E. H. (2000). Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14, 1988-1995.
140. Mühle, C., Huttner, H. B., Walter, S., Reichel, M., Canneva, F., Lewczuk, P., Gulbins, E., and Kornhuber, J. (2013). Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. PLoS One 8, e62912.
141. Mühle, C., Amova, V., Biermann, T., Bayerlein, K., Richter-Schmidinger, T., Kraus, T., Reichel, M., Gulbins, E., and Kornhuber, J. (2014). Sex-dependent decrease of sphingomyelinase activity during alcohol withdrawal treatment. Cell. Physiol. Biochem. 34, 71-81.
142. Murate, T., Suzuki, M., Hattori, M., Takagi, A., Kojima, T., Tanizawa, T., Asano, H., Hotta, T., Saito, H., Yoshida, S., et al. (2002). Up-regulation of acid sphingomyelinase during retinoic acidinduced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem. 277, 9936-9943.
143. Naghavi, M., John, R., Naguib, S., Siadaty, M. S., Grasu, R., Kurian, K. C., van Winkle, W. B., Soller, B., Litovsky, S., Madjid, M., et al. (2002). pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 164, 27-35.
144. Nelson, J. B., O'Hara, S. P., Small, A. J., Tietz, P. S., Choudhury, A. K., Pagano, R. E., Chen, X. M., and LaRusso, N. F. (2006). Cryptosporidium parvum infects human cholangiocytes via sphingolipidenriched membrane microdomains. Cell. Microbiol. 8, 1932-1945.
145. Newrzella, D. and Stoffel, W. (1996). Functional analysis of the glycosylation of murine acid sphingomyelinase. J. Biol. Chem. 271, 32089-32095.
146. Ni, X. and Morales, C. R. (2006). The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor. Traffic 7, 889-902.
147. Nielsen, M. S., Madsen, P., Christensen, E. I., Nykjaer, A., Gliemann, J., Kasper, D., Pohlmann, R., and Petersen, C. M. (2001). The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 20, 2180-2190.
148. Nishikawa, A., Gregory, W., Frenz, J., Cacia, J., and Kornfeld, S. (1997). The phosphorylation of bovine DNase I Asn-linked oligosaccharides is dependent on specific lysine and arginine residues. J. Biol. Chem. 272, 19408-19412.
149. Norman, E., Cutler, R. G., Flannery, R., Wang, Y., and Mattson, M. P. (2010). Plasma membrane sphingomyelin hydrolysis increases hippocampal neuron excitability by sphingosine-1-phosphate mediated mechanisms. J. Neurochem. 114, 430-439.
150. Nyberg, L., Farooqi, A., Bläckberg, L., Duan, R. D., Nilsson, A., and Hernell, O. (1998). Digestion of ceramide by human milk bile saltstimulated lipase. J. Pediatr. Gastroenterol. Nutr. 27, 560-567.
151. Oninla, V. O., Breiden, B., Babalola, J. O., and Sandhoff, K. (2014). Acid sphingomyelinase activity is regulated by membrane lipids and facilitates cholesterol transfer by NPC2. J. Lipid Res. 55, 2606-2619.
152. Öörni, K., Hakala, J. K., Annila, A., Ala-Korpela, M., and Kovanen, P. T. (1998). Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL). particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273, 29127-29134.
153. Öörni, K., Posio, P., Ala-Korpela, M., Jauhiainen, M., and Kovanen, P. T. (2005). Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler. Thromb. Vasc. Biol. 25, 1678-1683.
154. Otterbach, B. and Stoffel, W. (1995). Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81, 1053-1061.
155. Pan, W., Yu, J., Shi, R., Yan, L., Yang, T., Li, Y., Zhang, Z., Yu, G., Bai, Y., Schuchman, E. H., et al. (2014). Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron. Artery Dis. 25, 230-235.
156. Pavlu-Pereira, H., Asfaw, B., Poupctová, H., Ledvinová, J., Sikora, J., Vanier, M. T., Sandhoff, K., Zeman, J., Novotná, Z., Chudoba, D., et al. (2005). Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. A multiapproach study. J. Inherit. Metab. Dis. 28, 203-227.
157. Pavoine, C. and Pecker, F. (2009). Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc. Res. 82, 175-183.
158. Perrotta, C., Bizzozero, L., Cazzato, D., Morlacchi, S., Assi, E., Simbari, F., Zhang, Y., Gulbins, E., Bassi, M. T., Rosa, P., et al. (2010). Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J. Biol. Chem. 285, 40240-40251.
159. Petersen, C. M., Nielsen, M. S., Nykjaer, A., Jacobsen, L., Tommerup, N., Rasmussen, H. H., Roigaard, H., Gliemann, J., Madsen, P., and Moestrup, S. K. (1997). Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography. J. Biol. Chem. 272, 3599-3605.
160. Petersen, N. H. T., Olsen, O. D., Groth-Pedersen, L., Ellegaard, A. M., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013). Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24, 379-393.
161. Petrache, I., Natarajan, V., Zhen, L., Medler, T. R., Richter, A. T., Cho, C., Hubbard, W. C., Berdyshev, E. V., and Tuder, R. M. (2005). Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat. Med. 11, 491-498.
162. Pittis, M. G., Ricci, V., Guerci, V. I., Marcais, C., Ciana, G., Dardis, A., Gerin, F., Stroppiano, M., Vanier, M. T., Filocamo, M., et al. (2004). Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick type B patients and characterization of in vivo functional in-frame start codon. Hum. Mutat. 24, 186-187.
163. Plihtari, R., Hurt-Camejo, E., Öörni, K., and Kovanen, P. T. (2010). Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase. J. Lipid Res. 51, 1801-1809.
164. Ponting, C. P. (1994). Acid sphingomyelinase possesses a domain homologous to its activator proteins: saposins B and D. Protein Sci. 3, 359-361.
165. Popik, W., Alce, T. M., and Au, W. C. (2002). Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J. Virol. 76, 4709-4722.
166. Preuß, S., Omam, F. D., Scheiermann, J., Stadelmann, S., Winoto-Morbach, S., von Bismarck, P., Adam-Klages, S., Knerlich-Lukoschus, F., Lex, D., Wesch, D., et al. (2012). Topical application of phosphatidyl-inositol-3, 5-bisphosphate for acute lung injury in neonatal swine. J. Cell Mol. Med. 16, 2813-2826.
167. Qiu, H., Edmunds, T., Baker-Malcolm, J., Karey, K. P., Estes, S., Schwarz, C., Hughes, H., and Van Patten, S. M. (2003). Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J. Biol. Chem. 278, 32744-32752.
168. Quintern, L. E. and Sandhoff, K. (1991). Human acid sphingomyelinase from human urine. Methods Enzymol. 197, 536-540.
169. Quintern, L. E., Weitz, G., Nehrkorn, H., Tager, J. M., Schram, A. W., and Sandhoff, K. (1987). Acid sphingomyelinase from human urine: purification and characterization. Biochim. Biophys. Acta 922, 323-336.
170. Quon, D. V. K., Proia, R. L., Fowler, A. V., Bleibaum, J., and Neufeld, E. F. (1989). Proteolytic processing of the β-subunit of the lysosomal enzyme, β-hexosaminidase, in normal human fibroblasts. J. Biol. Chem. 264, 3380-3384.
171. Reagan, J. W., Jr., Hubbert, M. L., and Shelness, G. S. (2000). Posttranslational regulation of acid sphingomyelinase in niemann-pick type C1 fibroblasts and free cholesterol-enriched chinese hamster ovary cells. J. Biol. Chem. 275, 38104-38110.
172. Rees, D., Miles, E. A., Banerjee, T., Wells, S. J., Roynette, C. E., Wahle, K. W. J., and Calder, P. C. (2006). Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am. J. Clin. Nutr. 83, 331-342.
173. Reichel, M., Beck, J., Mühle, C., Rotter, A., Bleich, S., Gulbins, E., and Kornhuber, J. (2011). Activity of secretory sphingomyelinase is increased in plasma of alcohol-dependent patients. Alcohol. Clin. Exp. Res. 35, 1852-1859.
174. Reichel, M., Richter-Schmidinger, T., Mühle, C., Rhein, C., Alexopoulos, P., Schwab, S. G., Gulbins, E., and Kornhuber, J. (2014). The common acid sphingomyelinase polymorphism p. G508R is associated with self-reported allergy. Cell. Physiol. Biochem. 34, 82-91.
175. Reitman, M. L. and Kornfeld, S. (1981). UDP-N-acetylglucosamine: glycoprotein N-acetylglucosamine-1-phosphotransferase. Proposed enzyme for the phosphorylation of the high mannose oligosaccharide units of lysosomal enzymes. J. Biol. Chem. 256, 4275-4281.
176. Remmel, N., Locatelli-Hoops, S., Breiden, B., Schwarzmann, G., and Sandhoff, K. (2007). Saposin B mobilizes lipids from cholesterol-poor and bis (monoacylglycero) phosphate-rich membranes at acidic pH. Unglycosylated patient variant saposin B lacks lipid-extraction capacity. FEBS J. 274, 3405-3420.
177. Rhein, C., Tripal, P., Seebahn, A., Konrad, A., Kramer, M., Nagel, C., Kemper, J., Bode, J., Mühle, C., Gulbins, E., et al. (2012). Functional implications of novel human acid sphingomyelinase splice variants. PLoS One 7, e35467.
178. Rhein, C., Naumann, J., Mühle, C., Zill, P., Adli, M., Hegerl, U., Hiemke, C., Mergl, R., Möller, H. J., Reichel, M., et al. (2013). The acid sphingomyelinase sequence variation p. A487V is not associated with decreased levels of enzymatic activity. JIMD Rep 8, 1-6.
179. Rhein, C., Reichel, M., Mühle, C., Rotter, A., Schwab, S. G., and Kornhuber, J. (2014). Secretion of acid sphingomyelinase is affected by its polymorphic signal peptide. Cell. Physiol. Biochem. 34, 1385-1401.
180. Riethmüller, J., Riehle, A., Grassmé, H., and Gulbins, E. (2006). Membrane rafts in host-pathogen interactions. Biochim. Biophys. Acta 1758, 2139-2147.
181. Ro, H. A. and Carson, J. H. (2004). pH microdomains in oligodendrocytes. J. Biol. Chem. 279, 37115-37123.
182. Robciuc, A., Rantamäki, A. H., Jauhiainen, M., and Holopainen, J. M. (2014). Lipid-modifying enzymes in human tear fluid and corneal epithelial stress response. Invest. Ophthalmol. Vis. Sci. 55, 16-24.
183. Romiti, E., Vasta, V., Meacci, E., Farnararo, M., Linke, T., Ferlinz, K., Sandhoff, K., and Bruni, P. (2000). Characterization of sphingomyelinase activity released by thrombin-stimulated platelets. Mol. Cell Biochem. 205, 75-81.
184. Roth, A. G., Drescher, D., Yang, Y., Redmer, S., Uhlig, S., and Arenz, C. (2009a). Potent and selective inhibition of acid sphingomyelinase by bisphosphonates. Angew. Chem. Int. Ed. Engl. 48, 7560-7563.
185. Roth, A. G., Redmer, S., and Arenz, C. (2009b). Potent inhibition of acid sphingomyelinase by phosphoinositide analogues. Chem-BioChem 10, 2367-2374.
186. Roth, A. G., Redmer, S., and Arenz, C. (2010). Development of carbohydrate-derived inhibitors of acid sphingomyelinase. Bioorg. Med. Chem. 18, 939-944.
187. Rotolo, J. A., Zhang, J., Donepudi, M., Lee, H., Fuks, Z., and Kolesnick, R. (2005). Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J. Biol. Chem. 280, 26425-26434.
188. Sakuragawa, N. (1982). Acid sphingomyelinase of human placenta: purification, properties, and 125iodine labeling. J. Biochem. 92, 637-646.
189. Sakuragawa, N., Sato, M., Yoshida, Y., Kamo, I., Arima, M., and Satoyoshi, E. (1985). Effects of dimethylsulfoxide on sphingomyelinase in cultured human fibroblasts and correction of sphingomyelinase deficiency in fibroblasts from Niemann-Pick patients. Biochem. Biophys. Res. Commun. 126, 756-762.
190. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O. et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809.
191. Sathishkumar, S., Boyanovsky, B., Karakashian, A. A., Rozenova, K., Giltiay, N. V., Kudrimoti, M., Mohiuddin, M., Ahmed, M. M., and Nikolova-Karakashian, M. (2005). Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. Cancer Biol. Ther. 4, 979-986.
192. Sato, M., Yoshida, Y., Sakuragawa, N., and Arima, M. (1988). Effects of dimethylsulfoxide on sphingomyelinase activities in normal and Niemann-Pick type A, B and C fibroblasts. Biochim. Biophys. Acta 962, 59-65.
193. Satoi, H., Tomimoto, H., Ohtani, R., Kitano, T., Kondo, T., Watanabe, M., Oka, N., Akiguchi, I., Furuya, S., Hirabayashi, Y., et al. (2005). Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 130, 657-666.
194. Savic, R. and Schuchman, E. H. (2013). Use of acid sphingomyelinase for cancer therapy. In: The Role of Sphingolipids in Cancer Development and Therapy, J. S. Norris, ed. (Academic Press), pp. 91-115.
195. Sawashita, J., Takeda, A., and Okada, S. (1997). Change of zinc distribution in rat brain with increasing age. Brain Res. Dev. Brain Res. 102, 295-298.
196. 2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J. Biol. Chem. 271, 18431-18436.
197. Schissel, S. L., Tweedie-Hardman, J., Rapp, J. H., Graham, G., Williams, K. J., and Tabas, I. (1996b). Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J. Clin. Invest. 98, 1455-1464.
198. Schissel, S. L., Jiang, X., Tweedie-Hardman, J., Jeong, T., Camejo, E. H., Najib, J., Rapp, J. H., Williams, K. J., and Tabas, I. (1998a). Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273, 2738-2746.
199. Schissel, S. L., Keesler, G. A., Schuchman, E. H., Williams, K. J., and Tabas, I. (1998b). The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J. Biol. Chem. 273, 18250-18259.
200. Schneider, P. B. and Kennedy, E. P. (1967). Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J. Lipid Res. 8, 202-209.
201. Schramm, M., Herz, J., Haas, A., Krönke, M., and Utermöhlen, O. (2008). Acid sphingomyelinase is required for efficient phagolysosomal fusion. Cell Microbiol. 10, 1839-1853.
202. Schuchman, E. H. (2007). The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J. Inherit. Metab. Dis. 30, 654-663.
203. Schuchman, E. H. (2010). Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. FEBS Lett. 584, 1895-1900.
204. Schuchman, E. H. and Miranda, S. R. P. (1997). Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet. Test. 1, 13-19.
205. Schuchman, E. H., Suchi, M., Takahashi, T., Sandhoff, K., and Desnick, R. J. (1991). Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J. Biol. Chem. 266, 8531-8539.
206. Schwandner, R., Wiegmann, K., Bernardo, K., Kreder, D., and Krönke, M. (1998). TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase. J. Biol. Chem. 273, 5916-5922.
207. Seidel, D., Klenke, J., Fischer, G., and Pilz, H. (1978). An improved and simple micro-method of sphingomyelinase assay in leukocytes and urine. J. Clin. Chem. Clin. Biochem. 16, 407-411.
208. Sharom, F. J. (2011). Flipping and flopping-lipids on the move. IUBMB Life 63, 736-746.
209. Silver, I. A., Murrills, R. J., and Etherington, D. J. (1988). Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp. Cell Res. 175, 266-276.
210. Simon, C. G., Jr. and Gear, A. R. L. (1999). Sphingolipid metabolism during human platelet activation. Thromb. Res. 94, 13-23.
211. Simon, C. G., Jr., Chatterjee, S., and Gear, A. R. L. (1998). Sphingomyelinase activity in human platelets. Thromb. Res. 90, 155-161.
212. Simonaro, C. M., Desnick, R. J., McGovern, M. M., Wasserstein, M. P., and Schuchman, E. H. (2002). The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am. J. Hum. Genet. 71, 1413-1419.
213. Slotte, J. P., Härmälä, A. S., Jansson, C., and Pörn, M. I. (1990). Rapid turn-over of plasma membrane sphingomyelin and cholesterol in baby hamster kidney cells after exposure to sphingomyelinase. Biochim. Biophys. Acta 1030, 251-257.
214. Smith, E. L. and Schuchman, E. H. (2008). The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J. 22, 3419-3431.
215. Sneck, M., Nguyen, S. D., Pihlajamaa, T., Yohannes, G., Riekkola, M. L., Milne, R., Kovanen, P. T., and Öörni, K. (2012). Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH. J. Lipid Res. 53, 1832-1839.
216. Sorbi, D., Fadly, M., Hicks, R., Alexander, S., and Arbeit, L. (1993). Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 44, 1266-1272.
217. Sot, J., Ibarguren, M., Busto, J. V., Montes, L. R., Goñi, F. M., and Alonso, A. (2008). Cholesterol displacement by ceramide in sphingomyelin-containing liquid-ordered domains, and generation of gel regions in giant lipidic vesicles. FEBS Lett. 582, 3230-3236.
218. Spatola, M. and Wider, C. (2014). Genetics of Parkinson's disease: the yield. Parkinsonism Relat. Disord. 20(Suppl 1), S35-S38.
219. Spence, M. W., Burgess, J. K., and Sperker, E. R. (1979). Neutral and acid sphingomyelinases: somatotopographical distribution in human brain and distribution in rat organs. A possible relationship with the dopamine system. Brain Res. 168, 543-551.
220. 2+-stimulated sphingomyelinase in fetal bovine serum. J. Biol. Chem. 264, 5358-5363.
221. Staneva, G., Chachaty, C., Wolf, C., Koumanov, K., and Quinn, P. J. (2008). The role of sphingomyelin in regulating phase coexistence in complex lipid model membranes: competition between ceramide and cholesterol. Biochim. Biophys. Acta 1778, 2727-2739.
222. Staneva, G., Momchilova, A., Wolf, C., Quinn, P. J., and Koumanov, K. (2009). Membrane microdomains: role of ceramides in the maintenance of their structure and functions. Biochim. Biophys. Acta 1788, 666-675.
223. Steinert, S., Lee, E., Tresset, G., Zhang, D., Hortsch, R., Wetzel, R., Hebbar, S., Sundram, J. R., Kesavapany, S., Boschke, E., et al. (2008). A fluorescent glycolipid-binding peptide probe traces cholesterol dependent microdomain-derived trafficking pathways. PLOS One 3, e2933.
224. Swardfager, W., Herrmann, N., Mazereeuw, G., Goldberger, K., Harimoto, T., and Lanctôt, K. L. (2013a). Zinc in depression: a meta-analysis. Biol. Psychiatry 74, 872-878.
225. Swardfager, W., Herrmann, N., McIntyre, R. S., Mazereeuw, G., Goldberger, K., Cha, D. S., Schwartz, Y., and Lanctôt, K. L. (2013b). Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci. Biobehav. Rev. 37, 911-929.
226. Tabas, I. (1999). Secretory sphingomyelinase. Chem. Phys. Lipids 102, 123-130.
227. Tabas, I., Williams, K. J., and Borén, J. (2007). Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832-1844.
228. Takahashi, I., Takahashi, T., Abe, T., Watanabe, W., and Takada, G. (2000). Distribution of acid sphingomyelinase in human various body fluids. Tohoku J. Exp. Med. 192, 61-66.
229. Takahashi, T., Abe, T., Sato, T., Miura, K., Takahashi, I., Yano, M., Watanabe, A., Imashuku, S., and Takada, G. (2002). Elevated sphingomyelinase and hypercytokinemia in hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 24, 401-404.
230. Takahashi, I., Takahashi, T., Mikami, T., Komatsu, M., Ohura, T., Schuchman, E. H., and Takada, G. (2005). Acid sphingomyelinase: relation of 93lysine residue on the ratio of intracellular to secreted enzyme activity. Tohoku J. Exp. Med. 206, 333-340.
231. Takatsu, H., Tanaka, G., Segawa, K., Suzuki, J., Nagata, S., Nakayama, K. and Shin, H. W. (2014). Phospholipid flippase activities and substrate specificities of human type IV P-type ATPases localized to the plasma membrane. J. Biol. Chem. 289, 33543-33556.
232. Takeda, A., Sawashita, J., and Okada, S. (1994). Localization in rat brain of the trace metals, zinc and manganese, after intracerebroventricular injection. Brain Res. 658, 252-254.
233. Takeda, A., Sawashita, J., and Okada, S. (1995). Biological half-lives of zinc and manganese in rat brain. Brain Res. 695, 53-58.
234. Tam, C., Idone, V., Devlin, C., Fernandes, M. C., Flannery, A., He, X., Schuchman, E., Tabas, I., and Andrews, N. W. (2010). Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J. Cell Biol. 189, 1027-1038.
235. 2+ and sphingomyelinase in the repair of pore-forming toxin wounds. J. Vis. Exp. e50531.
236. Tamura, H., Takahashi, T., Ban, N., Torisu, H., Ninomiya, H., Takada, G., and Inagaki, N. (2006). Niemann-Pick type C disease: novel NPC1 mutations and characterization of the concomitant acid sphingomyelinase deficiency. Mol. Genet. Metab. 87, 113-121.
237. Tani, M. and Hannun, Y. A. (2007). Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization. J. Biol. Chem. 282, 10047-10056.
238. Tapper, H. and Sundler, R. (1992). Cytosolic pH regulation in mouse macrophages. Proton extrusion by plasma-membrane-localized H+-ATPase. Biochem. J. 281(Pt 1), 245-250.
239. te Vruchte, D., Speak, A. O., Wallom, K. L., Al Eisa N., Smith, D. A., Hendriksz, C. J., Simmons, L., Lachmann, R. H., Cousins, A., Hartung, R., et al. (2014). Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J. Clin. Invest. 124, 1320-1328.
240. Testai, F. D., Landek, M. A., Goswami, R., Ahmed, M., and Dawson, G. (2004). Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myoinositol 3, 4, 5-triphosphate in oligodendrocyte cell signaling. J. Neurochem. 89, 636-644.
241. Thomas, G. H., Tuck-Muller, C. M., Miller, C. S., and Reynolds, L. W. (1989). Correction of sphingomyelinase deficiency in Niemann-Pick type C fibroblasts by removal of lipoprotein fraction from culture media. J. Inherit. Metab. Dis. 12, 139-151.
242. Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., Schwille, P., Brügger, B., and Simons, M. (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247.
243. Trapp, S., Rosania, G. R., Horobin, R. W., and Kornhuber, J. (2008). Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 37, 1317-1328.
244. Truman, J. P., Al Gadban, M. M., Smith, K. J., Jenkins, R. W., Mayroo, N., Virella, G., Lopes-Virella, M. F., Bielawska, A., Hannun, Y. A., and Hammad, S. M. (2012). Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology 136, 30-45.
245. Utermöhlen, O., Karow, U., Löhler, J., and Krönke, M. (2003). Severe impairment in early host defense against Listeria monocytogenes in mice deficient in acid sphingomyelinase. J. Immunol. 170, 2621-2628.
246. van Meer, G., Voelker, D. R., and Feigenson, G. W. (2008). Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112-124.
247. Van Wart, H. E. and Birkedal-Hansen, H. (1990). The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87, 5578-5582.
248. Vanha-Perttula, T. (1988). Sphingomyelinases in human, bovine and porcine seminal plasma. FEBS Lett. 233, 263-267.
249. Vanha-Perttula, T., Rönkkö, S., and Lahtinen, R. (1990). Hydrolases from bovine seminal vesicle, prostate and Cowper's gland. Andrologia 22(Suppl 1), 10-24.
250. Vanier, M. T., Revol, A., and Fichet, M. (1980). Sphingomyelinase activities of various human tissues in control subjects and in Niemann-Pick disease - development and evaluation of a microprocedure. Clin. Chim. Acta 106, 257-267.
251. Vashum, K. P., McEvoy, M., Milton, A. H., McElduff, P., Hure, A., Byles, J., and Attia, J. (2014). Dietary zinc is associated with a lower incidence of depression: findings from two Australian cohorts. J. Affect. Disord. 166, 249-257.
252. Veiga, M. P., Arrondo, J. L. R., Goñi, F. M., and Alonso, A. (1999). Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys. J. 76, 342-350.
253. Verdurmen, W. P. R., Thanos, M., Ruttekolk, I. R., Gulbins, E., and Brock, R. (2010). Cationic cell-penetrating peptides induce ceramide formation via acid sphingomyelinase: implications for uptake. J. Control. Release 147, 171-179.
254. von Bismarck, P., Wistädt, C. F., Klemm, K., Winoto-Morbach, S., Uhlig, U., Schütze, S., Adam, D., Lachmann, B., Uhlig, S., and Krause, M. F. (2008). Improved pulmonary function by acid sphingomyelinase inhibition in a newborn piglet lavage model. Am. J. Respir. Crit. Care Med. 177, 1233-1241.
255. Wähe, A., Kasmapour, B., Schmaderer, C., Liebl, D., Sandhoff, K., Nykjaer, A., Griffiths, G., and Gutierrez, M. G. (2010). Golgi-tophagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin. J. Cell Sci. 123, 2502-2511.
256. Walters, M. J. and Wrenn, S. P. (2011). Mechanistic roles of lipoprotein lipase and sphingomyelinase in low density lipoprotein aggregation. J. Colloid Interface Sci. 363, 268-274.
257. Wan, Q. and Schuchman, E. H. (1995). A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. Biochim. Biophys. Acta 1270, 207-210.
258. Wasserstein, M. P., Aron, A., Brodie, S. E., Simonaro, C., Desnick, R. J., and McGovern, M. M. (2006). Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J. Pediatr. 149, 554-559.
259. Watanabe, K., Sakuragawa, N., Arima, M., and Satoyoshi, E. (1983). Partial purification and properties of acid sphingomyelinase from rat liver. J. Lipid Res. 24, 596-603.
260. Weinreb, N. J., Brady, R. O., and Tappel, A. L. (1968). The lysosomal localization of sphingolipid hydrolases. Biochim. Biophys. Acta 159, 141-146.
261. Weitz, G., Lindl, T., Hinrichs, U., and Sandhoff, K. (1983). Release of sphingomyelin phosphodiesterase (acid sphingomyelinase). by ammonium chloride from CL 1D mouse L-cells and human fibroblasts. Partial purification and characterization of the exported enzymes. Hoppe-Seylers Z. Physiol. Chem. 364, 863-871.
262. Weitz, G., Driessen, M., Brouwer-Kelder, E. M., Sandhoff, K., Barranger, J. A., Tager, J. M., and Schram, A. W. (1985). Soluble sphingomyelinase from human urine as antigen for obtaining anti-sphingomyelinase antibodies. Biochim. Biophys. Acta 838, 92-97.
263. Wenger, D. A., Sattler, M., Clark, C., and Wharton, C. (1976). I-cell disease: activities of lysosomal enzymes toward natural and synthetic substrates. Life. Sci. 19, 413-420.
264. Wong, M. L., Xie, B., Beatini, N., Phu, P., Marathe, S., Johns, A., Gold, P. W., Hirsch, E., Williams, K. J., Licinio, J., et al. (2000). Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc. Natl. Acad. Sci. USA 97, 8681-8686.
265. Wu, R. M., Lin, C. H., and Lin, H. I. (2014). The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 82, 283.
266. Xu, M., Xia, M., Li, X. X., Han, W. Q., Boini, K. M., Zhang, F., Zhang, Y., Ritter, J. K., and Li, P. L. (2012). Requirement of translocated lysosomal V1 H+-ATPase for activation of membrane acid sphingomyelinase and raft clustering in coronary endothelial cells. Mol. Biol. Cell 23, 1546-1557.
267. Yamamoto, K. (1994). Microbial endoglycosidases for analyses of oligosaccharide chains in glycoproteins. J. Biochem. 116, 229-235.
268. Yamanaka, T. and Suzuki, K. (1982). Acid sphingomyelinase of human brain: purification to homogeneity. J. Neurochem. 38, 1753-1764.
269. Yook, K., Harris, T. W., Bieri, T., Cabunoc, A., Chan, J., Chen, W. J., Davis, P., de la Cruz, N., Duong, A., Fang, R., et al. (2012). WormBase 2012: more genomes, more data, new website. Nucleic Acids Res. 40, D735-D741.
270. Yoshida, Y., Arimoto, K., Sato, M., Sakuragawa, N., Arima, M., and Satoyoshi, E. (1985). Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs. J. Biochem. (Tokyo) 98, 1669-1679.
271. Yu, J., Pan, W., Shi, R., Yang, T., Li, Y., Yu, G., Bai, Y., Schuchman, E. H., He, X., and Zhang, G. (2015). Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can. J. Cardiol., in press.
272. Zeidan, Y. H. and Hannun, Y. A. (2007a). Activation of acid sphingomyelinase by protein kinase Cd-mediated phosphorylation. J. Biol. Chem. 282, 11549-11561.
273. Zeidan, Y. H. and Hannun, Y. A. (2007b). Translational aspects of sphingolipid metabolism. Trends Mol. Med. 13, 327-336.
274. Zeidan, Y. H., Pettus, B. J., Elojeimy, S., Taha, T., Obeid, L. M., Kawamori, T., Norris, J. S., and Hannun, Y. A. (2006). Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-α-induced PGE2 production. J. Biol. Chem. 281, 24695-24703.
275. Zeidan, Y. H., Jenkins, R. W., and Hannun, Y. A. (2008a). Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J. Cell Biol. 181, 335-350.
276. Zeidan, Y. H., Wu, B. X., Jenkins, R. W., Obeid, L. M., and Hannun, Y. A. (2008b). A novel role for protein kinase Cδ-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. FASEB J. 22, 183-193.
277. Zha, X., Pierini, L. M., Leopold, P. L., Skiba, P. J., Tabas, I., and Maxfield, F. R. (1998). Sphingomyelinase treatment induces ATP-independent endocytosis. J. Cell Biol. 140, 39-47.